TRK Fusion Positive Cancers Grand Rounds
This program will review the use of CDK 4/6 inhibitors in the treatment of HR+/HER2-negative breast cancer and the management of treatment-related adverse events.
This program will review the use of CDK 4/6 inhibitors in the treatment of HR+/HER2-negative breast cancer and the management of treatment-related adverse events.
This live activity is focused on treatment strategies for patients with hepatocellular carcinoma (HCC).
This activity will cover the treatment and management of patients with non-small cell lung cancer (NSCLC).
This live activity will cover the treatment and management of patients with refractory metastatic colorectal cancer (CRC).
This activity will cover the treatment and management of patients with type 2 diabetes mellitus (T2DM).
This case-based live activity will cover the treatment and management of patients with hemophilia A
This activity will cover the treatment and management of patients with type 2 diabetes mellitus (T2DM).
This activity will cover the treatment and management of patients with type 2 diabetes mellitus (T2DM).
This live activity will cover the treatment and management of patients with refractory metastatic colorectal cancer (CRC).
This activity will cover the treatment and management of patients with non-metastatic castration-resistant prostate cancer (nmCRPC).
This activity will cover the treatment and management of patients with non-small cell lung cancer (NSCLC).